BRÈVE

sur SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma Names Tobias Erfurth as New Head of Investor Relations

SCHOTT Pharma AG & Co. KGaA announced the appointment of Tobias Erfurth as Head of Investor Relations, effective from August 2024. Tobias Erfurth will report directly to CFO Almuth Steinkühler and focus on strengthening the investor relations team.

Bringing over two decades of experience in finance, capital markets, and investor relations, Erfurth has notably led investor relations at Symrise AG for 13 years, aiding its growth into a DAX40 company. His prior role at Dresdner Bank and experiences surrounding the IPO of Crop Energies AG further underline his expertise.

CFO Almuth Steinkühler commented on the appointment, emphasizing Erfurth's substantial experience and potential to enhance SCHOTT Pharma's financial profile and market presence. Erfurth expressed enthusiasm about joining SCHOTT Pharma and contributing to its ongoing success in the pharmaceutical industry.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de SCHOTT Pharma AG & Co. KGaA